Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab plus Atezolizumab and Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer
NCT04256421Phase 3Completed
- Sponsor
- Roche
- Start
- Feb 2020
- Primary completion
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Tiragolumab + Atezolizumab + CE with Placebo + Atezolizumab + CE (2 arms). Primary endpoints: Progression-Free Survival up to 24 months and Overall Survival up to 24 months. Started Feb 2020; status: completed.
02
Drugs
tiragolumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04256421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04256421.